Page 3 - Alto Investors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alto investors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alto Investors Today - Breaking & Trending Today

Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells 3,000 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of […] ....

Daniel Faga , Stifel Nicolaus , Piper Sandler , First Light Asset Management , Securities Exchange Commission , Anaptysbio Inc , Millennium Management , Eventide Asset Management , Get Free Report , Exchange Commission , Light Asset Management , Asset Management , Palo Alto Investors , Alto Investors , Anaptysbio Daily , Nasdaq Anab , Insider Trading , Nsider Trades ,

HC Wainwright Reiterates "Buy" Rating for Gossamer Bio (NASDAQ:GOSS)

HC Wainwright Reiterates "Buy" Rating for Gossamer Bio (NASDAQ:GOSS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Silverarc Capital Management , Gossamer Bio Company Profile , Monashee Investment Management , Venture Management , Platinum Investment Management Ltd , Gossamer Bio Inc , Gossamer Bio , Free Report , Moderate Buy , Get Free Report , Capital Management , Investment Management , Alto Investors , Tyrosine Kinase , Gossamer Bio Daily ,

Sight Sciences (NASDAQ:SGHT) Announces Earnings Results

Sight Sciences (NASDAQ:SGHT – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13, Zacks reports. Sight Sciences had a negative return on equity of 40.69% and a negative net margin of 68.53%. The firm had revenue of $18.75 […] ....

Paul Badawi , News Ratings For Sight Sciences Daily , Earnings History For Sight Sciences , Sight Sciences , Voya Investment Management , Bridgeway Capital Management , Morgan Stanley , Barclays Plc , Sight Sciences Stock , Sight Sciences Company Profile , Sight Sciences Inc , Institutional Trading Of Sight Sciences , Vanguard Group Inc , Get Free Report , Alto Investors , Investment Management , Tearcare System , Sight Sciences Daily ,

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $21.00 at The Goldman Sachs Group

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $21.00 at The Goldman Sachs Group
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Iovance Biotherapeutics , Merrilla Mcpeak , Barclays Plc , Group Plc , Goldman Sachs Group , Iovance Biotherapeutics Inc , Chicago Partners Investment Group , Investment Group , Wells Fargo Company , Securities Exchange Commission , Get Free Report , Director Merrill , Exchange Commission , Partners Investment Group , Alto Investors , General Group Plc ,

Verve Therapeutics (NASDAQ:VERV) Shares Gap Up After Strong Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $14.44, but opened at $15.29. Verve Therapeutics shares last traded at $15.60, with a volume of 233,158 shares changing hands. The company reported ($0.69) EPS for […] ....

United States , William Blair , Royal Bank , Pricet Rowe Associates Inc , American International Group Inc , Verve Therapeutics Inc , Verve Therapeutics Company Profile , Sierra Summit Advisors , Group Plc , Verve Therapeutics , Get Free Report , International Group , Summit Advisors , Alto Investors , General Group Plc , Verve Therapeutics Daily ,